Travere Therapeutics

Travere cuts workforce by 20% as Filspari's prospects are up in one rare kidney disease, down in another
Fierce Pharma
Tue, 12/5/23 - 11:58 pm
Travere Therapeutics
Filspari
layoffs
Travere Touts Phase III Kidney Disease Data for Filspari After Trial Failures
BioSpace
Mon, 11/6/23 - 09:57 am
Travere Therapeutics
kidney disease
Filspari
clinical trials
As trial miss threatens FDA approval, Travere points to Filspari's benefits in bid to stay in kidney disease
Fierce Pharma
Fri, 11/3/23 - 10:53 am
Travere Therapeutics
Filspari
IgA nephropathy
kidney disease
FDA
Travere’s Kidney Disease Drug Narrowly Misses Phase III Endpoint, Stock Tanks
BioSpace
Thu, 09/21/23 - 06:34 pm
Travere Therapeutics
kidney disease
sparsentan
Filspari
clinical trials
Travere trips up but others are following in rare kidney disease
EP Vantage
Fri, 05/5/23 - 10:07 am
Travere Therapeutics
Filspari
focal segmental glomerulosclerosis
Travere’s FSGS therapy trial fails to meet primary efficacy endpoint
Clinical Trials Arena
Tue, 05/2/23 - 11:30 am
Travere Therapeutics
sparsentan
focal segmental glomerulosclerosis
clinical trials
Travere’s Filspari reduces urine protein levels in adults with IgAN
Clinical Trials Arena
Mon, 04/3/23 - 09:50 am
Travere Therapeutics
Filspari
IgA nephropathy
clinical trials
Biotech heads towards big catalysts
EP Vantage
Tue, 03/28/23 - 10:24 am
biotech
clinical trials
Alnylam Pharmaceuticals
Arcus Biosciences
Argenx
Arrowhead Pharmaceuticals
Axsome Therapeutics
Bavarian Nordic
FibroGen
Gilead Sciences
Incyte
Morphic Therapeutic
PTC Therapeutics
Syndax Pharmaceuticals
Travere Therapeutics
Vaxcyte
Biotech’s key upcoming clinical results
EP Vantage
Tue, 12/20/22 - 10:27 am
clinical trials
Acadia Pharmaceuticals
Argenx
Arrowhead Pharmaceuticals
Biomarin
BioNTech
Daiichi Sankyo
Day One
EQRx
Fate Therapeutics
FibroGen
Gilead Sciences
Idorsia
Immunogen
Intellia Therapeutics
Karuna Therapeutics
Moderna Therapeutics
Regeneron
Roche
Travere Therapeutics
Vaxcyte
FDA’s liver safety request set to delay decision on Travere’s kidney drug
Fierce Biotech
Sun, 10/16/22 - 05:12 pm
Travere Therapeutics
kidney disease
REMS
FDA
Brace for an end-of-year boost to drug approvals
EP Vantage
Fri, 09/2/22 - 12:14 pm
FDA
drug approvals
Alnylam Pharmaceuticals
Apellis Pharmaceuticals
Bristol Myers Squibb
Eli Lilly
Gilead Sciences
Mirati Therapeutics
Moderna Therapeutics
Provention Bio
Roche
TG Therapeutics
Travere Therapeutics
Travere fails to convince regulators to consider accelerated approval for a rare kidney disease — again
Endpoints
Thu, 08/4/22 - 10:56 am
Travere Therapeutics
Martin Shkreli
sparsentan
FDA
kidney disease
Vifor Licenses Rare Kidney Disease Drug in Comeback for Travere
BioSpace
Sat, 09/18/21 - 08:23 pm
Vifor Pharma
Travere Therapeutics
kidney disease
Several months after rebranding, an old Martin Skhreli company touts promising pivotal data in a rare kidney disorder
Endpoints
Mon, 08/16/21 - 12:12 pm
Calliditas
Martin Shkreli
Nefecon
Travere Therapeutics
FDA sets back Travere's plans for kidney disease drug approval
Fierce Biotech
Wed, 05/26/21 - 10:50 am
Travere Therapeutics
kidney disease
clinical trials
FDA
Retrophin
Martin Shkreli
Retrophin no more: Shkreli's legacy disappears as former company becomes Travere Therapeutics
Endpoints
Mon, 11/16/20 - 10:29 pm
Retrophin
Martin Shkreli
Travere Therapeutics